Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients: A GEICO Study. Issue 6 (1st August 2011)

• Record Type: Journal Article
• Authors: Oaknin, Ana; Roda, Desamparado; González-Martín, Antonio; Chiva, Luis; García-Donas, Jesús; de Juan, Ana; Redondo, Andrés; Martínez, Sergio; García, Yolanda; Catot, Sílvia; Ponce, Jordi; del Campo, J.M.; Cervantes, Andrés; Poveda, Andrés
• Is Part Of: International journal of gynecological cancer. Volume 21:Issue 6(2011)
• Page Start: 1048
• Page End: 1055
• Publication Date: 2011-08-01
• Subjects: Ovarian cancer -- Cisplatin -- Paclitaxel -- Modified chemotherapy regimen; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0b013e31821ee777
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. Methods: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen. Patients received IV paclitaxel 175 mg/m 2 over 3 hours on day 1, followed by IP cisplatin 100 mg/m 2 (or 75 mg/m 2 according to the principal investigator's criteria) on day 2. On day 8, patients received IP paclitaxel 60 mg/m 2 . To homogenize the IP administration and supportive measures, a GEICO guideline for IP chemotherapy was established. Patients were treated with the intention to receive 6 courses of chemotherapy every 21 days. Results: The median age of the patients was 49 years (range, 36-75 years), and most of them had papillary serous ovarian cancer (78%), International Federation of Gynecology and Obstetrics stage IIIC (76%). Thirty-nine patients completed 4 or more IP cycles, and 28 (61%) completed all 6 IP cycles. Twenty-two patients discontinued the IP/IV treatment, mainly because of chemotherapy toxicity (10 patients) and catheter-related complications (5 patients). The most prevalent grade 3/4 toxicities were neutropenia (14 patients; 30%) and gastrointestinal events (12 patients; 26%). Conclusions: The GEICO outpatient modified regimen resulted in a lesser toxicity and a greater rate of treatment completion than previously reported. The accurate selection of patients and the administration following well-defined guidelines can increase the feasibility of IP chemotherapy administration.